Anthony B. Semedo sold $74k of AORT
director at ARTIVION, INC.. 2,600 shares at an average of $28.47, traded May 23, 2025, filed May 27, 2025.
Score components
- +15RoleDirector
- +8Trade size$74k at market
- 0Share of holdings soldSold 7.3% of holdings
- +15Cluster3 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000784199-25-000092, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 23, 2025 | SOpen-market sale Common Stock | -2,600 | $28.47 | $74k | 33,059 | May 27, 2025 |
Related signals
Other insiders at ARTIVION, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 34Weak | AORTsell ARTIVION, INC. | Andrew M Green SVP, Regulatory and Quality | $287k 11,480 shares | -22% | |
| 32Weak | AORTsell ARTIVION, INC. | Andrew M Green SVP, Regulatory and Quality | $216k 8,003 shares | -13% | |
| 17Weak | ARTIVION, INC. | Marshall S. Stanton SVP, Clinical & MD Affair | $443k 15,000 shares | -19% | |
| 21Weak | ARTIVION, INC. | Marshall S. Stanton SVP, Clinical & MD Affair | $743k 26,132 shares | -25% | |
| 36Weak | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $254k 8,748 shares | -5% | |
| 44Moderate | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $288k 9,926 shares | -5% | |
| 44Moderate | ARTIVION, INC. | Marshall S. Stanton SVP, Clinical & MD Affair | $307k 10,548 shares | -9% | |
| 10Weak | ARTIVION, INC. | John E Davis Chief Commercial Officer | $357k 15,100 shares | -7% | |
| 12Weak | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $426k 18,020 shares | -8% | |
| 37Weak | ARTIVION, INC. | Jean F Holloway SVP, General Counsel | $53k 2,124 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.